ESR1 mutations are now established as a key mechanism of resistance to endocrine therapy in estrogen-receptor–positive breast cancer (ER​+ ​breast cancer) and their sensitive and specific detection in plasma-cell free DNA (plasma-cfDNA) is crucial to monitor during patient treatment. This evidence concerns the gene ESR1 and breast cancer.